Mandate

Vinge advises founder and major shareholders on the sale of Dynamic Code AB

September 17, 2021 M&A

Vinge is advising the founder and major shareholders in connection with the sale of Dynamic Code AB.

Dynamic Code develops and sells self-sampling kits based on DNA technology. The samples are analysed in Dynamic Code’s own lab and the test results are obtained through a code online. Care and treatment is thereafter offered via digital health care providers and Dynamic Code has, based on that, been able to create a complete chain of health care through its e-health platform.

Closing of the transaction is subject to due diligence and that shareholders representing 95 per cent of all shares in Dynamic Code adhere to the share transfer agreement.

The Vinge team includes Anna Edström, Magnus Hedsund and Niklas Törnell.

 

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025